AUPQ879500A0 - Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease - Google Patents

Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease

Info

Publication number
AUPQ879500A0
AUPQ879500A0 AUPQ8795A AUPQ879500A AUPQ879500A0 AU PQ879500 A0 AUPQ879500 A0 AU PQ879500A0 AU PQ8795 A AUPQ8795 A AU PQ8795A AU PQ879500 A AUPQ879500 A AU PQ879500A AU PQ879500 A0 AUPQ879500 A0 AU PQ879500A0
Authority
AU
Australia
Prior art keywords
presensitizer
hyaluronan
chemo
sensitizer
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPQ8795A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Meditech Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meditech Research Ltd filed Critical Meditech Research Ltd
Priority to AUPQ8795A priority Critical patent/AUPQ879500A0/en
Publication of AUPQ879500A0 publication Critical patent/AUPQ879500A0/en
Priority to CN01802357A priority patent/CN1388760A/zh
Priority to US10/088,774 priority patent/US20030180382A1/en
Priority to NZ517359A priority patent/NZ517359A/en
Priority to EP01951219A priority patent/EP1301209A4/en
Priority to JP2002511783A priority patent/JP5548328B2/ja
Priority to AU72202/01A priority patent/AU760404B2/en
Priority to PCT/AU2001/000849 priority patent/WO2002005852A1/en
Priority to GB0204331A priority patent/GB2368525B/en
Priority to CA2382560A priority patent/CA2382560C/en
Priority to ZA200201561A priority patent/ZA200201561B/en
Priority to US11/191,407 priority patent/US8287894B2/en
Priority to US11/198,663 priority patent/US9066919B2/en
Priority to US11/415,612 priority patent/US8388993B2/en
Priority to JP2012123354A priority patent/JP2012162569A/ja
Priority to US14/634,600 priority patent/US20150265648A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPQ8795A 2000-07-14 2000-07-14 Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease Abandoned AUPQ879500A0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AUPQ8795A AUPQ879500A0 (en) 2000-07-14 2000-07-14 Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CA2382560A CA2382560C (en) 2000-07-14 2001-07-13 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AU72202/01A AU760404B2 (en) 2000-07-14 2001-07-13 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
GB0204331A GB2368525B (en) 2000-07-14 2001-07-13 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
NZ517359A NZ517359A (en) 2000-07-14 2001-07-13 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP01951219A EP1301209A4 (en) 2000-07-14 2001-07-13 HYALURONAN AS A CYTOTOXIC AGENT, PRE-SENSITIZER TO DRUGS AND CHEMIO-SENSITIZER FOR THE TREATMENT OF DISEASES
JP2002511783A JP5548328B2 (ja) 2000-07-14 2001-07-13 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン
CN01802357A CN1388760A (zh) 2000-07-14 2001-07-13 在疾病治疗中作为胞毒剂,药物预致敏剂和化学致敏剂的透明质酸
PCT/AU2001/000849 WO2002005852A1 (en) 2000-07-14 2001-07-13 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US10/088,774 US20030180382A1 (en) 2000-07-14 2001-07-13 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
ZA200201561A ZA200201561B (en) 2000-07-14 2002-02-25 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of desease.
US11/191,407 US8287894B2 (en) 2000-07-14 2005-07-27 Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US11/198,663 US9066919B2 (en) 2000-07-14 2005-08-05 Hyaluronan as a chemo-sensitizer in the treatment of cancer
US11/415,612 US8388993B2 (en) 2000-07-14 2006-05-01 Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
JP2012123354A JP2012162569A (ja) 2000-07-14 2012-05-30 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン
US14/634,600 US20150265648A1 (en) 2000-07-14 2015-02-27 Hyaluronan as a chemo-sensitizer in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ8795A AUPQ879500A0 (en) 2000-07-14 2000-07-14 Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease

Publications (1)

Publication Number Publication Date
AUPQ879500A0 true AUPQ879500A0 (en) 2000-08-10

Family

ID=3822859

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPQ8795A Abandoned AUPQ879500A0 (en) 2000-07-14 2000-07-14 Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease

Country Status (10)

Country Link
US (3) US20030180382A1 (OSRAM)
EP (1) EP1301209A4 (OSRAM)
JP (2) JP5548328B2 (OSRAM)
CN (1) CN1388760A (OSRAM)
AU (1) AUPQ879500A0 (OSRAM)
CA (1) CA2382560C (OSRAM)
GB (1) GB2368525B (OSRAM)
NZ (1) NZ517359A (OSRAM)
WO (1) WO2002005852A1 (OSRAM)
ZA (1) ZA200201561B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
WO2003018062A1 (en) * 2001-08-27 2003-03-06 Meditech Research Limited Improved therapeutic protocols
CA2513143A1 (en) * 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
WO2007012133A1 (en) 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
MY149606A (en) * 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
JP2007153766A (ja) * 2005-12-01 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk Ｍａｐキナーゼキナーゼキナーゼ遺伝子の発現増強剤
EP2078528B1 (en) 2006-09-22 2013-08-14 Kochi University Radiation sensitizer or anti-cancer chemotherapy sensitizer
CA2713813C (en) * 2008-01-30 2017-12-05 University Of Kansas Intralymphatic chemotherapy drug carriers
WO2012104241A1 (de) 2011-01-31 2012-08-09 LUCOLAS-M.D. Ltd Kombinationen von aromatase inhibitoren und antioxidanzien
US9316645B2 (en) 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2014015264A1 (en) 2012-07-20 2014-01-23 Brown University Functionalized media and methods of making and using therefor
EP2712651A1 (en) 2012-09-27 2014-04-02 F. Hoffmann-La Roche AG Venting device for use in ambulatory infusion system
EP2712650A1 (en) 2012-09-27 2014-04-02 F. Hoffmann-La Roche AG Adapter and drug cartridge alignment device
WO2014126222A1 (ja) 2013-02-15 2014-08-21 国立大学法人高知大学 ハイドロゲルを担体として過酸化水素を徐放する腫瘍内局注用の放射線/化学療法増感剤
CN109528763A (zh) * 2018-12-29 2019-03-29 江苏靶标生物医药研究所有限公司 顺铂与透明质酸钠的组合物
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
WO2022173895A1 (en) * 2021-02-11 2022-08-18 Virginia Commonwealth University Methods for preventing cancer relapse

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA612307A (en) 1961-01-10 International Business Machines Corporation Hydraulic drive tape handling system
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
CA1227427A (en) 1984-08-16 1987-09-29 Albert Landsberger Therapeutic agent for the use in cancer treatment
JPS6191986U (OSRAM) 1984-11-24 1986-06-14
US5532341A (en) 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4665107A (en) 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
WO1998017320A1 (en) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5287123A (en) * 1992-05-01 1994-02-15 Hewlett-Packard Company Preheat roller for thermal ink-jet printer
JPH08508240A (ja) 1993-01-12 1996-09-03 ジョージ グリスティーナ，アンソニー 受動免疫の直接的濃厚伝達のための方法および組成物
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
US5847002A (en) 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2094203A1 (en) 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
AU2479695A (en) 1994-05-09 1995-11-29 Hadasit Medical Research Services & Development Company Ltd Prevention of tumor metastasis
KR970705401A (ko) 1994-08-30 1997-10-09 사무엘 시몬 에스큘라이 세포활성의 조정용 히알루론산과 그 유도체(hyaluronic acid and derivatives for modulation of cellular activity)
EP0871475A2 (en) 1995-09-14 1998-10-21 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
AU7161896A (en) * 1995-09-18 1997-04-09 Trustees Of Columbia University In The City Of New York, The Antiangiogenic properties of endothelial-monocyte activating polypeptide ii
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
PL326970A1 (en) 1995-12-01 1998-11-09 Hyal Pharma Corp Orientation of dosage of drugs and therapeutic agents as well as othe glykozaminoglykanes (gags)
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
CA2196370A1 (en) 1996-01-31 1997-08-01 Kohei Inomata Isoprene derivatives
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2189916C (en) 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
IT1286510B1 (it) 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono
EP0891775A4 (en) * 1996-12-27 2002-07-24 Seikagaku Kogyo Co Ltd MEDICINE FOR URBAN BLADDER DISORDERS
AU738788B2 (en) 1997-04-04 2001-09-27 Fidia Farmaceutici S.P.A. N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
JP2002526556A (ja) 1998-10-02 2002-08-20 ジェンザイム・コーポレーション 癒着の防止方法
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306643B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
SE9904121D0 (sv) 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
DK1250152T3 (da) 1999-12-28 2013-08-26 Bioniche Urology Ip Inc Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CA2437417C (en) 2001-02-22 2016-07-26 Anika Therapeutics, Inc. Thiol-modified hyaluronan
WO2003018062A1 (en) 2001-08-27 2003-03-06 Meditech Research Limited Improved therapeutic protocols
JP2005531502A (ja) 2002-02-15 2005-10-20 リサーチ　ディベロップメント　ファンデーション ヒアルロン酸媒介アデノウイルス形質導入
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
WO2007012133A1 (en) 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
MY149606A (en) 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Also Published As

Publication number Publication date
EP1301209A4 (en) 2005-11-09
WO2002005852A1 (en) 2002-01-24
US8388993B2 (en) 2013-03-05
US20030180382A1 (en) 2003-09-25
GB0204331D0 (en) 2002-04-10
CN1388760A (zh) 2003-01-01
US8287894B2 (en) 2012-10-16
ZA200201561B (en) 2003-11-25
US20060263395A1 (en) 2006-11-23
GB2368525B (en) 2004-08-11
CA2382560A1 (en) 2002-01-24
NZ517359A (en) 2003-11-28
JP5548328B2 (ja) 2014-07-16
GB2368525A (en) 2002-05-08
EP1301209A1 (en) 2003-04-16
JP2004502789A (ja) 2004-01-29
US20050267069A1 (en) 2005-12-01
CA2382560C (en) 2011-05-10
JP2012162569A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU4583601A (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2682401A (en) Flavonoid drug and dosage form, its production and use
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
AU2922600A (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU8028600A (en) Methods, pharmaceutical and therapeutic compositions for administering adenosine
AU2001237518A1 (en) Polyfluoroalkylimidazole derivatives, their preparation and therapeutic application
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
AU2002241416A1 (en) Dermatological agent for the treatment of skin trauma, especially in burn conditions
AU2003285125A1 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 7220201

Country of ref document: AU